ACY-1083 | CAS#1708113-43-2 | HDAC6 inhibitor

MedKoo Cat#: 462556 | Name: ACY-1083

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. It effectively reverses chemotherapy-induced peripheral neuropathy.

Chemical Structure

ACY-1083

CAS#1708113-43-2

Theoretical Analysis

MedKoo Cat#: 462556

Name: ACY-1083

CAS#: 1708113-43-2

Chemical Formula: C17H18F2N4O2

Exact Mass: 348.1398

Molecular Weight: 348.35

Elemental Analysis: C, 58.61; H, 5.21; F, 10.91; N, 16.08; O, 9.19

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 400.00	2 Weeks
5mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ACY-1083; ACY 1083; ACY1083

IUPAC/Chemical Name

2-((4,4-difluoro-1-phenylcyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide

InChi Key

MRWCVKLVSWYIFO-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H18F2N4O2/c18-17(19)8-6-16(7-9-17,13-4-2-1-3-5-13)22-15-20-10-12(11-21-15)14(24)23-25/h1-5,10-11,25H,6-9H2,(H,23,24)(H,20,21,22)

SMILES Code

FC(CC1)(F)CCC1(NC2=NC=C(C(NO)=O)C=N2)C3=CC=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 348.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Horndahl J, Svärd R, Berntsson P, Wingren C, Li J, Abdillahi SM, Ghosh B, Capodanno E, Chan J, Ripa L, Åstrand A, Sidhaye VK, Collins M. HDAC6 inhibitor ACY-1083 shows lung epithelial protective features in COPD. PLoS One. 2022 Oct 12;17(10):e0266310. doi: 10.1371/journal.pone.0266310. PMID: 36223404; PMCID: PMC9555642. 2: McAlpin BR, Mahalingam R, Singh AK, Dharmaraj S, Chrisikos TT, Boukelmoune N, Kavelaars A, Heijnen CJ. HDAC6 inhibition reverses long-term doxorubicin-induced cognitive dysfunction by restoring microglia homeostasis and synaptic integrity. Theranostics. 2022 Jan 1;12(2):603-619. doi: 10.7150/thno.67410. PMID: 34976203; PMCID: PMC8692908. 3: Nikolian VC, Dennahy IS, Weykamp M, Williams AM, Bhatti UF, Eidy H, Ghandour MH, Chtraklin K, Li Y, Alam HB. Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2019 Feb;86(2):232-239. doi: 10.1097/TA.0000000000002119. PMID: 30399139. 4: Krukowski K, Ma J, Golonzhka O, Laumet GO, Gutti T, van Duzer JH, Mazitschek R, Jarpe MB, Heijnen CJ, Kavelaars A. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017 Jun;158(6):1126-1137. doi: 10.1097/j.pain.0000000000000893. PMID: 28267067; PMCID: PMC5435512. 5: Porter NJ, Mahendran A, Breslow R, Christianson DW. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13459-13464. doi: 10.1073/pnas.1718823114. Epub 2017 Dec 4. PMID: 29203661; PMCID: PMC5754815. 6: Biesterveld BE, Wakam GK, Kemp MT, Williams AM, Shamshad A, O'Connell RL, Siddiqui AZ, Chtraklin K, Bhatti UF, Li Y, Alam HB. Histone deacetylase 6 inhibition improves survival in a swine model of lethal hemorrhage, polytrauma, and bacteremia. J Trauma Acute Care Surg. 2020 Nov;89(5):932-939. doi: 10.1097/TA.0000000000002677. PMID: 32195993. 7: Vieson MD, Gojmerac AM, Khan D, Dai R, van Duzer JH, Mazitschek R, Caudell DL, Liao X, Luo XM, Reilly CM. Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice. Histol Histopathol. 2017 Dec;32(12):1317-1332. doi: 10.14670/HH-11-885. Epub 2017 Feb 28. PMID: 28245046.